Viewing Study NCT06709495


Ignite Creation Date: 2025-12-24 @ 2:11 PM
Ignite Modification Date: 2026-02-21 @ 11:17 PM
Study NCT ID: NCT06709495
Status: RECRUITING
Last Update Posted: 2025-02-13
First Post: 2024-11-17
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Sponsor: David S Shulman, MD
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module